GRT Capital Partners L.L.C. purchased a new position in shares of Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 18,314 shares of the biopharmaceutical company’s stock, valued at approximately $114,000. GRT Capital Partners L.L.C. owned about 0.15% of Galmed Pharmaceuticals as of its most recent SEC filing.

Separately, KCG Holdings Inc. bought a new position in Galmed Pharmaceuticals in the 1st quarter worth approximately $100,000. Hedge funds and other institutional investors own 8.32% of the company’s stock.

Several research firms recently commented on GLMD. Maxim Group reaffirmed a “buy” rating and issued a $14.00 price objective (up from $9.00) on shares of Galmed Pharmaceuticals in a report on Monday, July 31st. Zacks Investment Research raised shares of Galmed Pharmaceuticals from a “hold” rating to a “buy” rating and set a $8.00 price objective for the company in a report on Wednesday, August 2nd. HC Wainwright lifted their price objective on shares of Galmed Pharmaceuticals from $12.00 to $18.00 and gave the stock a “buy” rating in a report on Tuesday, August 8th. Finally, ValuEngine raised shares of Galmed Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, June 17th.

TRADEMARK VIOLATION WARNING: “GRT Capital Partners L.L.C. Purchases New Position in Galmed Pharmaceuticals Ltd. (GLMD)” was originally posted by Daily Political and is owned by of Daily Political. If you are viewing this story on another publication, it was stolen and republished in violation of U.S. & international trademark and copyright law. The correct version of this story can be viewed at

Galmed Pharmaceuticals Ltd. (NASDAQ GLMD) opened at 7.83 on Friday. The stock’s market cap is $95.67 million. The firm has a 50 day moving average of $7.78 and a 200-day moving average of $6.01. Galmed Pharmaceuticals Ltd. has a 52-week low of $2.78 and a 52-week high of $8.87.

Galmed Pharmaceuticals (NASDAQ:GLMD) last announced its earnings results on Monday, July 31st. The biopharmaceutical company reported ($0.22) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.33) by $0.11. Galmed Pharmaceuticals had a negative net margin of 1,443.98% and a negative return on equity of 141.13%. The business had revenue of $0.27 million for the quarter, compared to the consensus estimate of $0.29 million. Equities analysts anticipate that Galmed Pharmaceuticals Ltd. will post ($0.94) earnings per share for the current fiscal year.

Galmed Pharmaceuticals Company Profile

Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol.

Institutional Ownership by Quarter for Galmed Pharmaceuticals (NASDAQ:GLMD)

Receive News & Ratings for Galmed Pharmaceuticals Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals Ltd. and related companies with's FREE daily email newsletter.